<?xml version="1.0" encoding="UTF-8"?>
<p>HIV-related morbidity and mortality started trending down eventually. The availability of several PIs and non-NRTIs, alongside NRTIs, started the era of combination antiretroviral therapy (ART) and declining AIDS deaths, reported for the first time in 1996 (
 <xref ref-type="fig" rid="F3">Figure 3</xref>). That same year, the FDA approved the first home (over-the-counter) HIV test, urine HIV test, and in vitro nucleic acid amplification test for plasma HIV-1 ribonucleic acid quantification (viral load) [
 <xref rid="CIT0033" ref-type="bibr">33</xref>]. Subsequently, new and improved ARVs have become available for therapy in terms of the following: potency, tolerability, safety, and resistance barrier; fixed-dose drug combinations; and novel ARV generations and classes (including integrase strand transfer inhibitors). Advances in prevention include the milestone approval for ARV PrEP of emtricitabine/tenofovir disoproxil fumarate in 2012 [
 <xref rid="CIT0033" ref-type="bibr">33</xref>]. Consequently, treatment and prevention paradigms have converged towards universal access, treatment as prevention, and combination prevention [
 <xref rid="CIT0034" ref-type="bibr">34</xref>].
</p>
